This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Argus II | |
|---|---|
| Name | Argus II Retinal Prosthesis System |
| Developer | Second Sight Medical Products |
| Introduced | 2011 |
| Country | United States |
| Type | Retinal prosthesis |
| Status | Discontinued (2019 commercial, limited research use) |
Argus II is a retinal prosthesis designed to restore a degree of visual perception to people with severe retinitis pigmentosa. The system combined an implanted electrode array with an external camera and processing unit to convert visual information into electrical stimulation of the retina. Developed by Second Sight Medical Products, the device was a focal point in translational research linking bioelectronic medicine, ophthalmology, and neuroengineering.
The Argus II concept emerged at the intersection of work by groups at California Institute of Technology, Massachusetts Institute of Technology, and industry teams led by Second Sight Medical Products. It targeted patients with advanced retinitis pigmentosa who retained residual inner retinal cells but had degenerated photoreceptors. Regulatory milestones include approval by the United States Food and Drug Administration via the premarket approval pathway and a CE mark from European Union notified bodies. Clinical adoption involved multidisciplinary centers such as Bascom Palmer Eye Institute, Moorfields Eye Hospital, and Massachusetts Eye and Ear.
The system comprised an external visual acquisition and processing unit and an implanted stimulation array. An external high-definition camera mounted on spectacle frames captured scenes and transmitted signals to a wearable video processing unit developed in collaboration with electronics teams experienced with Boston Scientific-scale implantable device engineering. Processed signals were sent via a radio-frequency coil to an implanted inductive coil and a retinal stimulator case. The implanted component included a 6x10 electrode array surgically tacked to the inner surface of the retina, manufactured using microfabrication techniques similar to those at Stanford University microelectronics facilities and material science groups at Cornell University. The device relied on biocompatible materials assessed with standards from the International Organization for Standardization and device testing practiced by regulatory consultants in Silicon Valley.
Surgical implantation was performed by vitreoretinal surgeons with techniques derived from pars plana vitrectomy practices established at centers like Wills Eye Hospital and Kresge Eye Institute. The electrode array was positioned over the macular region and secured with a retinal tack; the extraocular electronics were affixed to the sclera. Postoperative care involved immunologic monitoring informed by protocols from American Society of Retina Specialists and rehabilitation programs coordinated with low-vision services at institutions such as Smith-Kettlewell Eye Research Institute. Visual rehabilitation integrated mobility training used in programs at National Federation of the Blind and orientation strategies derived from research at University College London.
Pivotal trials were multicenter international studies enrolling patients across sites including Johns Hopkins Hospital, Wilmer Eye Institute, and Radboud University Medical Center. Endpoints emphasized safety and functional vision improvements measured with standardized tasks adopted from World Health Organization vision research and outcome measures from National Eye Institute. Data submitted to regulatory agencies led to FDA humanitarian device exemption considerations and CE certification across member states. Peer-reviewed reports appeared in journals associated with editorial boards from Nature Publishing Group and Elsevier-published ophthalmology titles.
Patients implanted with the system reported improved ability to detect high-contrast objects, localize light sources, and perform basic orientation tasks. Outcome metrics paralleled ones used in studies at Harvard Medical School and University of Oxford assessing mobility and object recognition. Quantitative gains varied across cohorts reported by teams at University of California, Los Angeles and University of Melbourne, with success correlated to residual retinal ganglion cell integrity studied in labs at Max Planck Society affiliates. Functional improvements enabled some recipients to read large print and perform activities of daily living with assistance, echoing rehabilitation outcomes reported by Liverpool Centre for Genomic Research collaborators in sensory substitution research.
Reported complications included conjunctival erosion, device dislocation, endophthalmitis risk similar to other intraocular implants, and necessity for revision surgery cited by surgeons at King's College London and Guy's and St Thomas' NHS Foundation Trust. Limitations were constrained spatial resolution from the 60-electrode array compared with natural acuity as defined by standards from International Council of Ophthalmology and intrinsic variability in cortical plasticity described by researchers at University of California, San Diego. Device longevity, power transfer constraints, and cost-effectiveness debates involved health technology assessment bodies such as National Institute for Health and Care Excellence.
The Argus II program evolved from academic prototypes to a commercial product through venture funding and strategic partnerships with industry actors in Los Angeles and San Francisco. Key figures included executives and scientists associated with Second Sight Medical Products and collaborators from University of Southern California. The product launched commercially in the early 2010s but faced market challenges, reimbursement hurdles with payers like Centers for Medicare & Medicaid Services, and was later withdrawn from general commercial distribution as the company shifted focus to next-generation approaches.
Follow-on research explored higher-density electrode arrays, subretinal vs epiretinal placement debated in laboratories at École Polytechnique Fédérale de Lausanne and Tokyo University Hospital, and alternative stimulation paradigms inspired by work at University of Pennsylvania and Duke University. Competing and successor technologies include subretinal implants developed by teams at RetroSense Therapeutics-related groups, cortical visual prostheses advanced by researchers at Brown University and Case Western Reserve University, and optogenetic strategies pursued at Genentech collaborations and academic labs at Rockefeller University. The Argus II legacy informs ongoing regulatory, surgical, and rehabilitation frameworks across translational neuroprosthetics.
Category:Retinal prostheses